- Home
- ABSI vs GLUE Comparison
ABSI vs GLUE Comparison
Compare ABSI & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- GLUE
- Stock Information
- Founded
- ABSI 2011
- GLUE 2019
- Country
- ABSI United States
- GLUE United States
- Employees
- ABSI N/A
- GLUE N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- GLUE Health Care
- Exchange
- ABSI Nasdaq
- GLUE Nasdaq
- Market Cap
- ABSI 338.0M
- GLUE 351.2M
- IPO Year
- ABSI 2021
- GLUE 2021
- Fundamental
- Price
- ABSI $2.39
- GLUE $4.80
- Analyst Decision
- ABSI Strong Buy
- GLUE Buy
- Analyst Count
- ABSI 5
- GLUE 2
- Target Price
- ABSI $7.98
- GLUE $13.50
- AVG Volume (30 Days)
- ABSI 4.4M
- GLUE 369.2K
- Earning Date
- ABSI 08-12-2025
- GLUE 08-07-2025
- Dividend Yield
- ABSI N/A
- GLUE N/A
- EPS Growth
- ABSI N/A
- GLUE N/A
- EPS
- ABSI N/A
- GLUE 0.29
- Revenue
- ABSI $4,138,000.00
- GLUE $177,986,000.00
- Revenue This Year
- ABSI $44.71
- GLUE $83.76
- Revenue Next Year
- ABSI $374.26
- GLUE N/A
- P/E Ratio
- ABSI N/A
- GLUE $16.32
- Revenue Growth
- ABSI 27.32
- GLUE 2990.57
- 52 Week Low
- ABSI $2.01
- GLUE $3.50
- 52 Week High
- ABSI $6.33
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- ABSI 33.33
- GLUE 51.69
- Support Level
- ABSI $2.50
- GLUE $4.54
- Resistance Level
- ABSI $2.73
- GLUE $4.93
- Average True Range (ATR)
- ABSI 0.18
- GLUE 0.21
- MACD
- ABSI -0.04
- GLUE 0.06
- Stochastic Oscillator
- ABSI 1.94
- GLUE 81.43
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.